Apogee Therapeutics, Inc. (APGE) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-24

Key Insights

Two board members (Andrew Gottesdiener, M.D. and Peter Harwin) are resigning effective May 11, 2026, reducing the board from nine to seven directors, which may signal internal restructuring or strategic shifts.
The company explicitly states the resignations are not due to disagreement on operations, policies, or practices, suggesting these are planned departures rather than contentious exits.
The board reduction to seven directors is a significant change in governance structure that could impact decision-making speed and oversight capabilities at the company.

Want the newest filings?

This analysis covers the filing from 2026-04-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-25

Apogee Therapeutics, Inc. has successfully raised $377.4 million through a public offering, which will provide additional capital to support the company's operations and drug development pipeline.
The company has granted the underwriters an option to purchase an additional 750,000 shares, which they have exercised in full, indicating strong investor demand for Apogee's stock.
The proceeds from the offering are expected to strengthen Apogee's financial position and enable the company to advance its drug candidates through clinical trials and towards potential commercialization.

Filed: 2026-03-23

Apogee Therapeutics announced positive maintenance data from the Phase 2 APEX clinical trial of its lead drug candidate zumilokibart (APG777) for atopic dermatitis, showing durable efficacy and tolerability over 52 weeks.
The company plans to initiate Phase 3 trials of zumilokibart in the second half of 2026, aiming for a potential commercial launch in 2029 in what it believes could be a $50 billion atopic dermatitis market.
Apogee also expects to report data from a Phase 1b head-to-head trial of its dual antibody candidate APG279 versus DUPIXENT in moderate-to-severe atopic dermatitis in the second half of 2026.

Filed: 2026-01-06

Apogee Therapeutics announced positive interim data from the Phase 1b clinical trial of its lead drug candidate zumilokibart (APG777) in patients with mild-to-moderate asthma, including favorable safety profile and robust suppression of FeNO, a key biomarker of Type 2 inflammation.
The company reported upcoming 2026 milestones, including data readouts from the Phase 2 APEX trial in atopic dermatitis and initiation of a Phase 3 trial in AD, potentially enabling a launch in 2029.
Apogee confirmed it believes it has sufficient cash runway to fund operations into the second half of 2028, providing visibility on the company's financial position to advance its pipeline.

Other reports for Apogee Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.